Quality of Life and Symptom Burden of Paroxysmal Nocturnal Haemoglobinuria Among Patients Receiving C5 Inhibitors in the United States and Europe (BSH 2022) - Apellis Medical Hub

Quality of Life and Symptom Burden of Paroxysmal Nocturnal Haemoglobinuria Among Patients Receiving C5 Inhibitors in the United States and Europe

Share Via Email

Back to Conference Resources

PNH Congress Presentations British Society for Haematology (BSH) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.